Canlorbe Geoffroy, Bendifallah Sofiane, Raimond Emilie, Graesslin Olivier, Hudry Delphine, Coutant Charles, Touboul Cyril, Bleu Géraldine, Collinet Pierre, Darai Emile, Ballester Marcos
Department of Obstetrics and Gynaecology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), Paris, France,
Ann Surg Oncol. 2015 Aug;22(8):2714-21. doi: 10.1245/s10434-014-4295-0. Epub 2014 Dec 12.
Studies focusing on the impact of obesity on survival in endometrial cancer (EC) have reported controversial results and few data exist on the impact of obesity on recurrence rate and recurrence-free survival (RFS). The aim of this study was to assess the impact of obesity on surgical staging and RFS in EC according to the European Society of Medical Oncology (ESMO) risk groups.
Data of 729 women with EC who received primary surgical treatment between January 2000 and December 2012 were abstracted from a multicenter database. RFS distributions according to body mass index (BMI) in each ESMO risk group were estimated using the Kaplan-Meier method. Survival was evaluated using the log-rank test, and the Cox proportional hazards model was used to determine influence of multiple variables.
Distribution of the 729 women with EC according to BMI was BMI < 30 (n = 442; 60.6 %), 30 ≤ BMI < 35 (n = 146; 20 %) and BMI ≥ 35 (n = 141; 19.4 %). Nodal staging was less likely to be performed in women with a BMI ≥ 35 (72 %) than for those with a BMI < 30 (90 %) (p < 0.0001). With a median follow-up of 27 months (interquartile range 13-52), the 3-year RFS was 84.5 %. BMI had no impact on RFS in obese women in the low-/intermediate-risk groups, but a BMI ≥ 35 was independently correlated to a poorer RFS (hazard ratio 12.5; 95 % confidence interval 3.1-51.3) for women in the high-risk group.
Severe obesity negatively impacts RFS in women with high-risk EC, underlining the importance of complete surgical staging and adapted adjuvant therapies in this subgroup of women.
关于肥胖对子宫内膜癌(EC)患者生存影响的研究结果存在争议,且肥胖对复发率和无复发生存期(RFS)影响的数据较少。本研究旨在根据欧洲医学肿瘤学会(ESMO)风险分组评估肥胖对EC手术分期及RFS的影响。
从一个多中心数据库中提取了2000年1月至2012年12月期间接受初次手术治疗的729例EC女性患者的数据。采用Kaplan-Meier法估计各ESMO风险组中根据体重指数(BMI)划分的RFS分布情况。使用对数秩检验评估生存率,并采用Cox比例风险模型确定多个变量的影响。
729例EC女性患者按BMI分布为BMI < 30(n = 442;60.6%),30≤BMI < 35(n = 146;20%)和BMI≥35(n = 141;19.4%)。BMI≥35的女性(72%)比BMI < 30的女性(90%)进行淋巴结分期的可能性更低(p < 0.0001)。中位随访27个月(四分位间距13 - 52个月),3年RFS为84.5%。BMI对低/中风险组肥胖女性的RFS无影响,但对于高风险组女性,BMI≥35与较差的RFS独立相关(风险比12.5;95%置信区间3.1 - 51.3)。
严重肥胖对高危EC女性的RFS有负面影响,突显了该亚组女性进行完整手术分期及适当辅助治疗的重要性。